By Professor Elgene Lim

Journal articles

Collier A; Chavez Mac Gregor M; Hilz S; Bardia A; Sohn J; Martin M; Lim E; Martinalbo J; Perez-Moreno PD; Moore HM, 2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC).', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1069

Karimi L; Alves CL; Terp MG; Tuttolomondo M; Portman N; Ehmsen S; Johansen LE; Bak M; Lim E; Ditzel HJ, 2023, 'Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor', Cancer Communications, 43, pp. 720 - 725, http://dx.doi.org/10.1002/cac2.12425

André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I, 2023, 'Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial', Lancet, 401, pp. 1773 - 1785, http://dx.doi.org/10.1016/S0140-6736(23)00725-0

Conway JRW; Warren SC; Lee YK; McCulloch AT; Magenau A; Lee V; Metcalf XL; Stoehr J; Haigh K; Abdulkhalek L; Guaman CS; Reed DA; Murphy KJ; Pereira BA; Mélénec P; Chambers C; Latham SL; Lenthall H; Deenick EK; Ma Y; Phan T; Lim E; Joshua AM; Walters S; Grey ST; Shi YC; Zhang L; Herzog H; Croucher DR; Philp A; Scheele CLGJ; Herrmann D; Sansom OJ; Morton JP; Papa A; Haigh JJ; Nobis M; Timpson P, 2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063

Lim E; Hamilton E; Palmieri C; Arkenau H-T; Brook S; Fisher G; Mazur A, 2023, 'A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT1-02-02

Lim E; Chavez M; Bardia A; Sohn JH; Moore HM; Shivhare M; Martinalbo J; Roncoroni L; Perez-Moreno PD; Martin M, 2023, 'Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy for previously treated, estrogen receptor+, HER2-advanced breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD13-04

Downton T; Karlsen E; Cuff K; Walpole E; Simpson F; Lim E, 2023, 'HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT2-10-05

Jhaveri K; Wang H-C; Ma C; Lim E; Tao JJ; Manso L; Pierga J-Y; Parajuli R; Gilarranz YJ; Lu Y-S; Beeram M; Larson T; Dhakal A; Ismail-Khan R; Karacsonyi C; Cao S; Osborne C; Estrem ST; Nguyen B; Li Y, 2023, 'Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD13-12

Chen J; Wu S; Ruan T; Slapetova I; Millar E; Lim E; Swarbrick A, 2023, 'Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD9-01

Krop I; Park YH; Kim S-B; Borges G; Aksoy S; Gregori JG; Roylance R; Lim E; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Takano T; Egorov A; Wu I; Cathcart J; Chu C; Andre F, 2023, 'Trastuzumab deruxtecan vs physician's choice in patients with HER2+unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-GS2-01

Downton T; Segara D; Ong A; Bingham J; Carson E-K; Chen J; Middleton K; Lindeman G; Parker A; Lim E, 2023, 'WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT2-01-10

Zhou FH; Downton T; Freelander A; Hurwitz J; Caldon CE; Lim E, 2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1148792

Neven P; Hamilton E; Pistilli B; Borges V; Campone M; Foukakis T; Kodahl AR; Lau PKH; Lim E; Lugowska I; Collins J; Gresty C; Miller C; Sommavilla R; Sudhan D; Rugo HS, 2023, '206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292', ESMO Open, 8, pp. 101395 - 101395, http://dx.doi.org/10.1016/j.esmoop.2023.101395

Martin Jimenez M; Hilz S; Collier A; Chibly A; Sohn J; Bardia A; Lim E; Mac Gregor MC; Martinalbo J; Perez-Moreno PD; Moore HM, 2023, 'Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC', ANNALS OF ONCOLOGY, 34, pp. S356 - S357, http://dx.doi.org/10.1016/j.annonc.2023.09.590

Jhaveri K; Jeselsohn R; Ma CX; Lim E; Yonemori K; Hamilton EP; Harnden K; Im S-A; Beck T; Sammons S; Bhave M; Kaufman PA; Saura Manich C; Meniawy T; Bacchion F; Ismail-Khan R; Li Y; Estrem ST; Nguyen B; Beeram M, 2023, 'Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-advanced breast cancer (aBC): Results from the phase Ia/b EMBER', ANNALS OF ONCOLOGY, 34, pp. S338 - S339, http://dx.doi.org/10.1016/j.annonc.2023.09.560

Chen J; Ruan T; Wu S; Lim E; Swarbrick A, 2023, 'Targeting stromal cells to reverse immune suppression in triple-negative breast cancer', ANNALS OF ONCOLOGY, 34, pp. S190 - S190, http://dx.doi.org/10.1016/j.annonc.2023.09.1514

Wong V; de Boer R; Baron-Hay S; Blum R; Boyle F; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott L; Nottage M; Tafreshi A; Tsoi D; Uccellini A; Hong W; Gibbs P; Lok SW, 2022, 'Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer', Clinical Breast Cancer, 22, pp. 792 - 800, http://dx.doi.org/10.1016/j.clbc.2022.08.011

Papanicolaou M; Parker AL; Yam M; Filipe EC; Wu SZ; Chitty JL; Wyllie K; Tran E; Mok E; Nadalini A; Skhinas JN; Lucas MC; Herrmann D; Nobis M; Pereira BA; Law AMK; Castillo L; Murphy KJ; Zaratzian A; Hastings JF; Croucher DR; Lim E; Oliver BG; Mora FV; Parker BL; Gallego-Ortega D; Swarbrick A; O’Toole S; Timpson P; Cox TR, 2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Chapman SC; Gable JC; Chen Y; Price GL; Hossain AM; Gainford MC; Ezquerra MB, 2022, 'An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer', Breast Cancer Research and Treatment, 195, pp. 275 - 287, http://dx.doi.org/10.1007/s10549-022-06690-5

Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L, 2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772

Berthelet J; Foroutan M; Bhuva DD; Whitfield HJ; El-Saafin F; Cursons J; Serrano A; Merdas M; Lim E; Charafe-Jauffret E; Ginestier C; Ernst M; Hollande F; Anderson RL; Pal B; Yeo B; Davis MJ; Merino D, 2022, 'Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14102404

Morrow RJ; Allam AH; Yeo B; Deb S; Murone C; Lim E; Johnstone CN; Ernst M, 2022, 'Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones', Cancers, 14, http://dx.doi.org/10.3390/cancers14092292

Portman N; Lim E, 2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, 3, pp. 138 - 140, http://dx.doi.org/10.1038/s43018-021-00328-z

Haggstrom LR; Vardy JL; Carson EK; Segara D; Lim E; Kiely BE, 2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14, http://dx.doi.org/10.3390/cancers14040920

Brown LJ; Achinger-Kawecka J; Portman N; Clark S; Stirzaker C; Lim E, 2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474

Dinh P; Graham JD; Elder EN; Kabir M; Doan TB; French J; Meybodi F; Hui R; Wilcken NR; Harnett PR; Hsu J; Stuart KE; Wang T; Ahern V; Brennan M; Fox SB; Dear RF; Lim E; White M; Mann GB; Pathmanathan N, 2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511, http://dx.doi.org/10.1007/s10549-021-06456-5

Downton T; Zhou F; Segara D; Jeselsohn R; Lim E, 2022, 'Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status', Drug Design Development and Therapy, 16, pp. 2933 - 2948, http://dx.doi.org/10.2147/DDDT.S380925

Martin Jimenez M; Lim E; Mac Gregor MC; Bardia A; Wu J; Zhang Q; Nowecki Z; Cruz F; Safin R; Kim S-B; Schem C; Montero A; Khan S; Bandyopadhyay R; Shivhare M; Patre M; Martinalbo J; Roncoroni L; Perez-Moreno PD; Sohn J, 2022, 'Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study', ANNALS OF ONCOLOGY, 33, pp. S633 - S634, http://dx.doi.org/10.1016/j.annonc.2022.07.250

Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J; Jimenez MM; Johnston S; Boyle F; Neven P; Jiang Z; Campone M; Huober J; Shimizu C; Cicin I; Wardley A; Abuin GG; Zarba J; Lim E; Sant P; Liao N; Christiansen B; Eigeliene N; Martin-Babau J; Ettl J; Mavroudis D; Chiu J; Boer K; Nagarkar R; Paluch-Shimon S; Moscetti L; Sagara Y; Kim SB; Maciel MM; Tjan-Heijnen V; Broom R; Lacko A; Schenker M; Volkov N; Sim Yap Y; Coccia-Portugal M; Ángel García Sáenz J; Andersson A; Chao TY; Gokmen E; Harputluoglu H; Berzoy O; Patt D; McArthur H; Chew H; Chalasani P; Kaufman P; Tedesco K; Graff SL, 2021, 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study', Annals of Oncology, 32, pp. 1571 - 1581, http://dx.doi.org/10.1016/j.annonc.2021.09.015

Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25422-9

Wu SZ; Roden DL; Al-Eryani G; Bartonicek N; Harvey K; Cazet AS; Chan CL; Junankar S; Hui MN; Millar EA; Beretov J; Horvath L; Joshua AM; Stricker P; Wilmott JS; Quek C; Long GV; Scolyer RA; Yeung BZ; Segara D; Mak C; Warrier S; Powell JE; O’Toole S; Lim E; Swarbrick A, 2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z

Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ, 2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23, http://dx.doi.org/10.1186/s13058-021-01461-4

Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ, 2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25901-z

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; Serra V; Waring P; Lim E; Caldon CE, 2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', Npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x

Portman N; Chen J; Lim E, 2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.777867

Brown LJ; Meredith T; Yu J; Patel A; Neal B; Arnott C; Lim E; Yu J, 2021, 'Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis of randomized trials', Cancers, 13, pp. 5527, http://dx.doi.org/10.3390/cancers13215527

Kumar S; Freelander A; Lim E, 2021, 'Type 1 nuclear receptor activity in breast cancer: Translating preclinical insights to the clinic', Cancers, 13, pp. 4972, http://dx.doi.org/10.3390/cancers13194972

Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722

Wu SZ; Al-Eryani G; Roden DL; Junankar S; Harvey K; Andersson A; Thennavan A; Wang C; Torpy JR; Bartonicek N; Wang T; Larsson L; Kaczorowski D; Weisenfeld NI; Uytingco CR; Chew JG; Bent ZW; Chan CL; Gnanasambandapillai V; Dutertre CA; Gluch L; Hui MN; Beith J; Parker A; Robbins E; Segara D; Cooper C; Mak C; Chan B; Warrier S; Ginhoux F; Millar E; Powell JE; Williams SR; Liu XS; O’Toole S; Lim E; Lundeberg J; Perou CM; Swarbrick A, 2021, 'A single-cell and spatially resolved atlas of human breast cancers', Nature Genetics, 53, pp. 1334 - 1347, http://dx.doi.org/10.1038/s41588-021-00911-1

Chen J; Colosimo M; Lim E, 2021, 'The management of HER2-positive early breast cancer: Current and future therapies', Asia Pacific Journal of Clinical Oncology, 17, pp. 3 - 12, http://dx.doi.org/10.1111/ajco.13655

Ardolino L; Lau B; Wilson I; Chen J; Borella L; Stone E; Lim E, 2021, 'Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.701424

Jhaveri KL; Lim E; Hamilton EP; Saura C; Meniawy T; Jeselsohn R; Beck JT; Kaufman PA; Sammons S; Banda K; Okera M; Yonemori K; Harnden KK; Kim S-B; Sohn J; Ma CX; Aftimos PG; Wang XA; Young SRL; Beeram M, 2021, 'A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER plus advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1050

Martin M; Lim E; Mac Gregor MC; Shivhare M; Ross G; Patre M; Roncoroni L; Louka M; Sohn J, 2021, 'acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS1100

Wong V; de Boer R; Baron-Hay SE; Blum RH; Forster BC; Chua SLL; Cuff K; Green M; Lim E; Mok K; Nott LM; Nottage MK; Tafreshi A; Tsoi DTF; Yeo B; Gibbs P; Lok SW, 2021, 'Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.e13018

Palmieri C; Linden HM; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb PW; Jain K; Vogel CL; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR plus /estrogen receptor (ER) plus breast cancer in an international phase 2 clinical study.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1020

Jhaveri KL; Boni V; Sohn J; Villanueva-Vasquez R; Bardia A; Schmid P; Lim E; Patel JM; Alejandro Perez-Fidalgo J; Loi S; Im S-A; Kshirsagar S; Gates MR; Bond J; Eng-Wong J; Chang C-W; Turner NC; Lopez Miranda E; Garcia-Estevez L; Bellet M, 2021, 'Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.1017

Freelander A; Brown LJ; Parker A; Segara D; Portman N; Lau B; Lim E, 2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, 12, pp. 1 - 24, http://dx.doi.org/10.3390/genes12020285

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

Hui R; de Boer R; Lim E; Yeo B; Lynch J, 2021, 'CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care', Asia Pacific Journal of Clinical Oncology, 17, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13555

Back to profile page